Two patterns of ion channelopathy in the myocardium: Perspectives for development of anti-arrhythmic agents

Current Opinion in Investigational Drugs

Volumn 6, Issue 3, 2005, Pages 289-297

  Dai, De Zai ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Cardiac arrhythmias; Cardiac sarcoplasmic; FK 506 binding protein 12.6; Ion channels; Phospholamban; Reticulum calcium ATPase; Ryanodine receptor 2

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; ALPHA TOCOPHEROL; AMIODARONE; ANTIARRHYTHMIC AGENT; ASCORBIC ACID; AZIMILIDE; BEPRIDIL; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CALCIUM CHANNEL; CATECHOLAMINE; CPU 86017; DOFETILIDE; DRONEDARONE; ENCAINIDE; ENDOTHELIN RECEPTOR ANTAGONIST; FLAVONOID; FLECAINIDE; IBUTILIDE; ION CHANNEL; ISOPRENALINE; LEVOTHYROXINE; PHOSPHOLAMBAN; POLYPHENOL DERIVATIVE; POTASSIUM; POTASSIUM CHANNEL; PROBUCOL; PROPRANOLOL; SODIUM; SODIUM CHANNEL; SOTALOL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACTION POTENTIAL; ANTIARRHYTHMIC ACTIVITY; ARRHYTHMOGENESIS; BINDING SITE; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; DIASTOLE; DOWN REGULATION; DRESSLER SYNDROME; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; ELECTROSTIMULATION; ENZYME PHOSPHORYLATION; GENE MUTATION; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART CYCLE; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART INFARCTION; HEART MUSCLE; HEART REPOLARIZATION; HEART VENTRICLE FLUTTER; HEART VENTRICLE HYPERTROPHY; HUMAN; INCIDENCE; MORBIDITY; MORTALITY; NONHUMAN; OXIDATIVE STRESS; POTASSIUM CURRENT; PROTEIN BINDING; RADIOFREQUENCY ABLATION; RECEPTOR AFFINITY; REENTRY ARRHYTHMIA; REVIEW; RR INTERVAL; SARCOPLASMIC RETICULUM; SIDE EFFECT; SUDDEN DEATH; TORSADE DES POINTES; UPREGULATION;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; CALCIUM CHANNELS; CALCIUM-TRANSPORTING ATPASES; CARDIOMEGALY; HUMANS; ION CHANNELS; MUSCLE PROTEINS; MYOCARDIUM; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SARCOPLASMIC RETICULUM; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; TACROLIMUS BINDING PROTEINS;

EID: 15844389497     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Roden DM, Balser JR, George AL Jr, Anderson ME: Cardiac ion channels Annu Rev Physiol (2002) 64:431-475.
2. Olson EN: A decade of discoveries in cardiac biology. Nat Med (2004) 10(5):467-474.
3. Marban E: Cardiac channelopathies. Nature (2002) 415 6868):213-218.
4. Colatsky TJ: Antiarrhythmic drugs: Where are we going? Pharmaceutical News (1995) 2(5):17-23.
5. Guerra PG, Talajic M, Roy D, Dubuc M, Thibault B, Nattel S: Is there a future for antiarrhythmic drug therapy? Drugs (1998) 56 5):767-781.
6. No author listed: Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med (1989) 321 6):406-412.
7. Van Gelder IC, Brugemann J, Crijns HJ: Current treatment recommendations in antiarrhythmic therapy. Drugs (1998) 55 3):331-346.
8. No authors listed: The 'Sicilian Gambit'. A now approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation (1991) 84 4):1831-1851.
9. Roden DM, Lazzara R, Rosen M, Schwartz PJ, Towbin J, Vincent GM: Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. Circulation (1996) 94(8):1996-2012.
10. + channels. Circ Res (1998) 82(3):386-395.
11. Priori SG, Napolitano C, Paganini V, Cantu F, Schwartz PJ: Molecular biology of the long QT syndrome: Impact on management. Pacing Clin Electrophysiol (1997) 20(2):2052-2057.
12. Dumaine R, Antzelevitch C: Molecular mechanisms underlying the long QT syndrome. Curr Opin Cardiol (2002) 17(1):36-42.
13. Bennet PB, Yazawa K, Makita N, George AL Jr. Molecular mechanism for an inherited cardiac arrhythmia. Nature (1995) 376 6542):683-685.
14. Nabauer M, Kaab S: Potassium channel down-regulation in heart failure Cardiovasc Res (1998) 37(2):324-334.
15. Qin DY, Zhang ZH, Caref EB, Boutjdir M, Jain P, Ei-Sherif N: Cellular and ionic basis of arrhythmias in postinfarction remodeled ventricular myocardium. Circ Res (1996) 79(3):461-473.
16. Tomita F, Bassett AL, Myerburg RJ, Kimura S: Diminished transient outward currents in rat hypertrophied ventricular myocytes. Circ Res (1994) 75(2):296-303.
17. Lucchesi BR: Sudden coronary death: Pharmacological interventions for the prevention of ventricular fibrillation. TIPS (1984) 5 4):145-148.
18. Dai DZ, Zong JG, Lei HY, Bai MQ, Rong P: Changes of superoxide dismutase, malondialdehyde, creatine phosphokinase in non-infarcted zone of an infarcted heart in rats and drug treatment. J Chin Pharmaceut Univ (1995) 26(5):291-296.
19. Dai DZ, Rong P, Shen W: Effect of tetra-hydro-berberine derivative on the morphological changes of acute myocardial infarction in rats. J Chin Pharmaceut Univ (1989) 20(5):278-282.
20. Carmeliet E: Mechanisms and control of repolarization. Eur Heart J (1993) 14(Suppl H):3-13.
21. Dai DZ, Wang YQ: Cardiac arrhythmias (the basic portion). In: Ion Channels and Cardio-Cerebrovascular Diseases: Basic Science and Clinical Practice. Jia HQ, Wang ZL, Yang QD (Eds), The People's Health Publishing House, Beijing, China (2001):178-197.
22. Willich SN, Maclure M, Mittleman M, Amtz HR, Muller JE: Sudden cardiac death support for a role of triggering in causation. Circulation (1993) 87(5):1442-1450.
23. Dai DZ, Hu HQ, Yang P, Ma YP, Cao W, Wang H: The proarrhythmic activity and the ion channelopethy in remodeled myocardium. Chin J Pathophysiol (2000) 16(10):945-948.
24. Kambouris NG, Nuss HB, Johns DC, Tomaselli GF, Marban E, Balser JR: Phenotypic characterization of a novel long-QT syndrome mutation (R16230) in the cardiac sodium channel. Circulation (1998) 97(7):640-644.
25. Dai DZ: Vulnerable substrate and multiple ion channel disorder in a diseased heart will be now targets for antiarrhythmic therapy. Acta Pharmacol Sin (2000) 21(4):289-295.
26. Dai DZ: Disordered ion channels and antiarrhythmic agents. Pharmaceut News (2001) 8(2):1-6.
27. Dai DZ: The now targets for development of antiarrhythmic agents. J Chin Pharmaceut Univ (2002) 33(3):173-177.
28. Dai DZ: The ion channelopathy and reconsideration of antiarrhythmic drugs. In: Advances in Pharmacology. Su DF, Miao ZY, Wang YM (Eds), The People's Health Publishing House, Beijing, China (2002):202-211.
29. Yu F, Dai DZ, An LF, Guo XF: Heart hypertrophy induced by levothyroxine aggravates ischemic lesions and reperfusion arrhythmias in rats. Zhongguo Yao Li Xue Bao (1997) 18(1):71-74.
30. +-ATPase activity induced by L-thyroxin in rats. Chin J Pharmacol Toxicol (1995) 9(4):228-230.
31. 2+-ATPase activity elevation. Zhongguo Yao Li Xue Bao (1996) 17(6):516-518.
32. Ma YP, Hao XM, Zhang GQ, Zhou PA, Wu CH, Dai DZ: Blocking effect of CPU 86017 on slowly activated rectifier potassium current in single ventricular myocytes of guinea pigs. J Chin Pharmaceut Univ (2000) 31(2):121-125.
33. Dai DZ, Hu HJ, Yang DM, Hao XM, Zhang GQ, Zhou PA, Wu CH: Chronic levothyroxin treatment is associated with ion channel abnormalities in cardiac and neuronal cells. Clin Exp Pharmacol Physiol (1999) 26(10):819-821.
34. Berger RD, Kasper EK, Baughman KL, Marban E, Calkins H, Tomaselli GF: Beat-to-beat QT interval variability: Novel evidence for repolarization lability in ischemic and nonischemic dilated cardiomyopathy. Circulation (1997) 96(5):1557-1565.
35. + current in dogs with chronic complete atrioventricular block and acquired Torsades de Pointes. Circulation (1999) 100(24):2455-2461.
36. Tomaselli GF, Beuckelmann DJ, Calkins HG, Berger RD, Kessler PD, Lawrence JH, Kass D, Feldman AM, Marban E: Sudden cardiac death in heart failure. The role of abnormal repolarization. Circulation (1994) 90(5):2534-2539.
37. Dai DZ, Yu F, Li HT, Tang YQ, An LF, Huang WL, Peng SX, Hao XM, Zhou BA, Hu CH: Blockade on sodium, potassium, and calcium channels by a new antiarrhythmic agent CPU 86017. Drug Dev Res (1996) 39 2):138-146.
38. Wang HL, Li SB, Dai DZ: Change of L-type calcium current in single guinea pig hypertrophic ventricular myocytes induced by levothyroxin. J Chin Pharmaceut Univ (2000) 31:130-134.
39. Lu HR, Yu F, Dai DZ, Remeysen P, De Clerck F: Reduction in QT dispersion and ventricular arrhythmias by ischaemic preconditioning in anaesthetized, normotensive and spontaneously hypertensive rats. Fundam Clin Pharmacol (1999) 13(4):445-454.
40. Marx SO, Reiken S, Hisamatsu Y, Jayamana T, Burkhoff D, Rosemblit N, Marks AR: PKA phosphorylation dissociated FKBP12.6 from the calcium release channel (ryanodine receptor) defective regulation in failing hearts. Cell (2000) 101(4):365-376.
41. Wehrens XH, Lehnart SE, Huang F, Vest JA, Reiken SR, Mohler PJ, Sun J, Guatimosim S, Song LS, Rosemblit N, D'Armiento JM et al: FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell (2003) 113(7):829-840.
42. Scoote M, Willians AJ: The cardiac ryanodine receptor (calcium release channel): Emerging role in heart failure and arrhythmia pathogenesis. Cardiovasc Res (2002) 56(3):359-372.
43. Paul M, Schulze-Bahr E, Breithardt G, Wichter T: Genetics of arrhythmogenic right ventricular cardiomyopathy-status quo and future perspectives. Z Kardiol (2003) 92(2):3628-3649.
44. Ahmad F: The molecular genetics of arrhythmogenic right ventricular dysplasia-cardiomyopathy. Clin Invest Med (2003) 26 4):167-178.
45. Dulac Y, Acar P, Delay M: Diagnosis of adrenergic ventricular tachycardia in two homozygotic twins. Arch Mal Coeur Vaiss (2003) 96(5):521-523.
46. Lahat H, Pras E, Eldar M: RYR2 and CASQ2 mutations in patients suffering from catecholaminergic polymorphic ventricular tachycardia. Circulation (2003) 107(3):e29.
47. Hoit BD, Tramuta DA, Kadambi VJ, Dash R, Ball N, Kranias EG, Walsh RA: Influence of transgenic overexpression of phospholamban on post-extrasystolic potentiation. J Mol Cell Cardiol (1999) 31(11):2007-2015.
48. Antos CL, Frey N, Marx SO, Reiken S, Gaburjakova M, Richardson JA, Marks AR, Olson EN: Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase A. Circ Res (2001) 89(11):997-1004.
49. Wang HL, Dai DZ, Gao E, Zhang YP, Lu F: Dispersion of ventricular mRNA of RyR2, and SERCA2 associated with arrhythmogenesis in rats. Acta Pharmacol Sin (2004) 25(6):738-743.
50. Wu XD, Dai DZ, Zhang QP, Gao F: Propranolol and verapamil inhibit mRNA expression of RyR2 and SERCA in L-thyroxin-induced rat ventricular hypertrophy. Acta Pharmacol Sin (2004) 25(3):347-351.
51. 2+-ATPase mRNA expression and biphasic force-frequency relations in patients with hypertrophic cardiomyopathy. Circulation (2001) 104(6):658-663.
52. George CH, Higgs GV, Lai FA: Ryanodine receptor mutations associated with stress-induced ventricular tachycardia mediate increased calcium release in stimulated cardiomyocytes. Circ Res (2003) 93 6):531-540.
53. Cui YJ, Yang P, Dai DZ, Gao L, Xiao DW, Wang YQ: CPU 86017 suppresses tachyarrhythmias induced by ouabain and myocardial infarction: Concentrations in plasma and different areas of the heart in dogs. Drug Dev Res (2003) 58(1):131-137.
54. De Ponti F, Poluzzi E, Vaccherri A, Bergman U, Bjerrum L, Ferguson J, Frenz KJ, McManus P, Schubert I, Selke G, Terzis-Vaslamatzis G et al Non-antiarrhythmic drugs prolonging the QT interval: Considerable use in seven countries. Br J Clin Pharmacol (2002) 54 2):171-177.
55. Howard PA: Ibutilide: An antiarrhythmic agent for the treatment of atrial fibrillation or flutter. Ann Pharmacother (1999) 33 1):38-47.
56. Wang T, Wang ZJ, Dai DZ: Comparison of effects of dofetilide derivative V03 (CPU 228) and dofetilide on coronary occlusion and reperfusion arrhythmia, vascular contractions and pro-arrhythmic potential of Torsades de Pointes. Chinese Pharmacol Bulletin (2004) 20:516-520.
57. Brendorp B, Elming H, Jun L, Kober L, Torp-Pedersen C:The prognostic value of QTc interval and QT dispersion following myocardial infarction in patients treated with or without dofetilide. Clin Cardiol (2003) 26(5):219-225.
58. Yoshida H, Sugiyama A, Satoh Y, Ishida Y, Yoneyama M, Kugiyama K, Hashimoto K: Comparison of the in vivo electrophysiological and proarrhythmic effects of amiodarone with those of a selective class III drug, sematilide, using a canine chronic atrioventricular block model Circulation J (2002) 66(8):758-762.
59. Doggrell SA, Hancox JC: Dronedarone: An amiodarone analogue. Expert Con Investig Drugs (2004) 13(4):415-426.
60. Fermini B, Jurkiewicz NK, Jow B, Guinosso PJ Jr, Baskin EP, Lynch JJ Jr, Salata JJ: Use-dependent effects of the class III antiarrhythmic agent NE-10064 (azimilide) on cardiac repolarization: Block of delayed rectifier potassium and L-type calcium currents. J Cardiovasc Pharmacol (1995) 26(2):259-271.
61. Dai DZ: The antiarrhythmic activity of protoberberines in relation to blockade of ion channels. Ion Channel Modulators ID Res Alert (1997) 2(10):383-390.
62. Hallman K, Carlsson L: Prevention of class III-induced pro-arrhythmias by flecainide in an animal model of the acquired long QT syndrome. Pharmacol Toxicol (1995) 77(4):250-254.
63. Dai DZ, An LF, Huang DY, Sun RY: Orthogonal analysis of aggravating effects of α,β-agonists and leukocytes on reperfusion-induced arrhythmias and ventricular fibrillation in Langendorff's rat heart. Zhongguo Yao Li Xue Bao (1996) 17(2):145-148.
64. Dai DZ, Zhang GQ, Yang P, Ma YP: Two patterns of ion channelopathies relating to arrhythmias and direct and indirect blockade of ion channels by antiarrhythmic agents. Drug Dev Res (2003) 58(1):42-50.
65. + current in guinea pig hypertrophied ventricular myocytes induced by thyroxine. Chin Pharmacol Bull (2001) 17(2):1-4.
66. Torre-Amione G, Young JB, Durand JB, Bozkurt B, Mann DL, Kobrin I, Pratt CM: Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure. Circulation (2001) 103(7):973-980.
67. Miyauchi T, Goto K: Heart failure and endothelin receptor antagonists Trends Pharmacol Sci (1999) 20(5):210-217.
68. Dai DZ, Huang M, Ji M, Liu LG: A novel endothelin receptor antagonist CPU 0213 and therapeutic effect on acute heart failure in rats. Acta Pharmacol Sin (2005): manuscript submitted.
69. Saavedra WF, Paolocci N, St John ME, Skaf MW, Stewart GC, Xie JS, Harrison RW, Zeichner J, Mudrick D, Marban E, Kass DA et al: Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ Res (2002) 90(3):297-304.
70. 2+exchanger expression and function in an arrhythmogenic rabbit model of heart failure. Circ Res (1999) 85(1):1009-1019.
71. 2+ exchange. Circ Res (2002) 90(9):988-995.
72. 2+ exchanger. J Mol Cell Cardiol (2001) 33(12):2071-2074.
73. Beatch GN, Barret TD, Plouvier B, Jung G, Wall RA, Zolotoy A, Walker MJ: Ventricular fibrillation, an uncontrolled arrhythmia seeking new targets. Drug Dev Res (2002) 55(1):45-52.
74. Karmarzyn M: Antiarrhythmic effects of Na-H exchange inhibition. Drug Dev Res (2002) 55(1):22-28.
75. Sia YT, Lapointe N, Parker TG, Tsoporis JN, Deschepper CF, Calderone A, Pourdjabbar A, Jasmin JF, Sarrazin JF, Liu P, Adam A et al: Beneficial effects of long-term use of the antioxidant probucol in heart failure in the rat. Circulation (2002) 105(21):2549-2555.
76. Marks AR, Reiken S, Marx SO: Progression of heart failure: Is protein kinase A hyperphosphorylation of the ryanodine receptor a contributing factor? Circulation (2002) 105(3):272-275.
77. Nemec J, Shen WK: Antiarrhythmic drugs: New agents and evolving concepts. Expert Opin Investig Drugs (2003) 12(3):435-453.